Long-term safety of aromatase inhibitors in the treatment of breast cancer

References

• AgnelliGVenous thromboembolism and cancer:a two-way clinical associationThromb Haemost199778117209198139
   PubMed Web of Science ®Google Scholar
• AllredDCMohsinSFuquaSAHistological and biological evolution of human premalignant breast diseaseEndocr Relat Cancer20018476111350726
   PubMed Web of Science ®Google Scholar
• AndreFSlimaneKBachelotTBreast cancer with synchronous metastases:trends in survival during a 14-year periodJ Clin Oncol2004223302815310773
   PubMed Web of Science ®Google Scholar
• ParkinDMBrayFFerlayJPisaniPGlobal cancer statisticsCA Cancer J Clin2005557410815761078
   PubMed Web of Science ®Google Scholar
• ATAC Trialists’ GroupAnastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer:first results of the ATAC randomised trialLancet20023592131912090977
   PubMed Web of Science ®Google Scholar
• ATAC Trialists’ GroupAnastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early-stage breast cancer. Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial efficacy and safety update analysesCancer20039818021014584060
   PubMed Web of Science ®Google Scholar
• ATAC Trialists’ GroupResults of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years’ adjuvant treatment for breast cancerLancet200536560215639680
   PubMed Web of Science ®Google Scholar
• ATAC Trialists’ GroupComprehensive side-effect profile of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer:long-term safety analysis of the ATAC trialLancet Oncol200676334316887480
   PubMed Web of Science ®Google Scholar
• AtalayGDirixLBiganzoliLThe effect of exemestane on serum lipid profile in postmenopausal women with metastatic breast cancer:a companion study to EORTC Trial 10951, ‘Randomized phase II study in first line hormonal treatment for metastatic breast cancer with exemestane or tamoxifen in postmenopausal patients’Ann Oncol200415211714760111
   PubMed Web of Science ®Google Scholar
• BanerjeeSSmithIEFolkerdLComparative effects of anastrozole, tamoxifen alone and in combination on plasma lipids and bone-derived resorption during neoadjuvant therapy in the impact trialAnn Oncol2005161632816030027
   PubMed Web of Science ®Google Scholar
• BeatsonGOn the treatment of inoperable cases of carcinoma of the mamma:suggestions for a new method of treatment, with illustrative casesLancet189621047
   Google Scholar
• BissettDDavisJGeorgeWDGynaecological monitoring during tamoxifen therapyLancet1994344124497967983
   PubMed Web of Science ®Google Scholar
• BoccardoFRubagottiAPuntoniMSwitching to anastrozole versus continued tamoxifen treatment of early breast cancer:preliminary results of the Italian Tamoxifen Anastrozole TrialJ Clin Oncol2005a2351384716009955
   PubMed Web of Science ®Google Scholar
• BoccardoFMRubagottiAPuntoniMSwitching to anastrozole (ANA) vs continued tamoxifen (TAM) treatment of early breast cancer (EBC). Updated results of the Italian tamoxifen anastrozole (ITA) trialJ Clin Oncol2005b23526 Meeting Abstracts
   Web of Science ®Google Scholar
• BoluferPRicartELluchAAromatase activity and estradiol in human breast cancer:its relationship to estradiol and epidermal growth factor receptors and to tumor-node-metastasis stagingJ Clin Oncol199210438461740683
   PubMed Web of Science ®Google Scholar
• BonneterreJThurlimannBRobertsonJFAnastrozole versus tamoxifen as first-line therapy for advanced breast cancer in 668 postmenopausal women:results of the Tamoxifen or Arimidex Randomized Group Efficacy and Tolerability studyJ Clin Oncol20001837485711078487
   PubMed Web of Science ®Google Scholar
• BonneterreJBuzdarANabholtzJMAnastrozole is superior to tamoxifen as first-line therapy in hormone receptor positive advanced breast carcinomaCancer20019222475811745278
   PubMed Web of Science ®Google Scholar
• BuzdarAURobertsonJFEiermannWAn overview of the pharmacology and pharmacokinetics of the newer generation aromatase inhibitors anastrozole, letrozole, and exemestaneCancer20029520061612404296
   PubMed Web of Science ®Google Scholar
• BuzdarAUon behalf of the ATAC Trialists’ GroupClinical features of joint symptoms observed in the ‘Arimidex, Tamoxifen, Alone or in Combination’ (ATAC trialJ Clin Oncol20062418s551
   Google Scholar
• CellaDFallowfieldLBarkerPQuality of life of postmenopausal women in the ATAC (“Arimidex”, Tamoxifen, Alone or in Combination) trial after completion of (years’ adjuvant treatment for early breast cancerBreast Cancer Res Treat20061002738416944295
   PubMed Web of Science ®Google Scholar
• CoatesAKeshaviahAThurlimannBFive years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer:update of study BIG 1–98J Clin Oncol2007254869217200148
   PubMed Web of Science ®Google Scholar
• ColozzaMCardosoFSotiriouCBringing molecular prognosis and prediction to the clinicClin Breast Cancer20056617615899074
   PubMedGoogle Scholar
• CoombesRCHallEGibsonLJA randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancerN Engl J Med200435010819215014181
   PubMed Web of Science ®Google Scholar
• CoombesRCKilburnLSSnowdonCSurvival and safety of exemestane versus tamoxifen after 2–3 years’ tamoxifen treatment (Intergroup Exemestane Study):a randomized controlled trialLancet200736970
   Web of Science ®Google Scholar
• DewarJNabholtzJ-MABonneterreJThe effect of anastrozole (Arimidex™) on serum lipids - data from a randomized comparison of anastrozole (AN) vs Tamoxifen (TAM) in postmenopausal (PM) women with advanced breast cancer (ABC)Breast Cancer Res Treat200064SupplS51
   Google Scholar
• [EBCTCG] Early Breast Cancer Trialists’ Collaborative GroupEffects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trialsLancet2005365168771715894097
   PubMed Web of Science ®Google Scholar
• ElisafMSBairaktariETNicolaidesCEffect of letrozole on the lipid profile in postmenopausal women with breast cancerEur J Cancer200137121510311506958
   PubMed Web of Science ®Google Scholar
• Endogenous Hormones and Breast Cancer Collaborative GroupEndogenous sex hormones and breast cancer in postmenopausal women:reanalysis of nine prospective studiesJ Natl Cancer Inst2002946061611959894
   PubMed Web of Science ®Google Scholar
• EnganTKraneJJohannessenDCPlasma changes in breast cancer patients during endocrine therapy – lipid measurements and nuclear magnetic resonance (NMR) spectroscopyBreast Cancer Res Treat199536287978573711
   PubMed Web of Science ®Google Scholar
• FallowfieldLJBlissJMPorterLSQuality of life in the Intergroup Exemestane Study:a randomized trial of exemestane versus continued tamoxifen after 2 to 3 years of tamoxifen in postmenopausal women with primary breast cancerJ Clin Oncol2006249101716484701
   PubMed Web of Science ®Google Scholar
• FisherBDignamJBryantJFive versus more than five years of tamoxifen therapy for breast cancer patients with negative lymph nodes and estrogen receptor-positive tumorsJ Natl Cancer Inst1996881529428901851
   PubMed Web of Science ®Google Scholar
• FisherBJeongJHBryantJTreatment of lymph-node-negative, oestrogen-receptor-positive breast cancer:long-term findings from National Surgical Adjuvant Breast and Bowel Project randomised clinical trialsLancet20043648586815351193
   PubMed Web of Science ®Google Scholar
• GeislerJHaynesBAnkerGInfluence of letrozole and anastrozole on total body aromatization and plasma estrogen levels in postmenopausal breast cancer patients evaluated in a randomized, cross-over studyJ Clin Oncol200220751711821457
   PubMed Web of Science ®Google Scholar
• GnantMJakeszRMlineritschBZoledronic acid effectively counteracts cancer treatment induced bone loss (CTIBL) in premenopausal breast cancer patients receiving adjuvant endocrine treatment with goserelin plus anastrozole versus goserelin plus tamoxifen – bone density subprotocol results of a randomized multicenter trial (ABCSG-12)Breast Cancer Res Treat200488S8
   Web of Science ®Google Scholar
• GorodeskiGIUpdate on cardiovascular disease in post-menopausal womenBest Pract Res Clin Obstet Gynaecol2002163295512099666
   PubMed Web of Science ®Google Scholar
• GossPEIngleJNMartinoSA randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancerN Engl J Med2003349179380214551341
   PubMed Web of Science ®Google Scholar
• GossPEIngleJNMartinoSRandomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer:updated findings from NCIC CTG MA 17J Natl Cancer Inst20059712627116145047
   PubMed Web of Science ®Google Scholar
• JakeszRJonatWGnantMSwitching of postmenopausal women with endocrine-responsive early breast cancer to anastrozole after 2 years’ adjuvant tamoxifen:combined results of ABCSG trial 8 and ARNO 95 trialLancet2005a3664556216084253
   PubMed Web of Science ®Google Scholar
• JakeszRSamoniggHGreilRExtended adjuvant treatment with anastrozole:Results from the Austrian Breast and Colorectal Cancer Study Group Trial 6a (ABCSG-6a)J Clin Oncol2005b23527 Meeting Abstracts
   Google Scholar
• KatajaVHietanenPJoensuuHThe effects of adjuvant anastrozole, exemestane, tamoxifen, and toremifene on serum lipids in postmenopausal women with breast cancer – a randomised studyBreast Cancer Res Treat200276Suppl 1S156
   Google Scholar
• LevineMNPrevention of thrombotic disorders in cancer patients undergoing chemotherapyThromb Haemost19977813369198142
   PubMed Web of Science ®Google Scholar
• LockerGYEastellRThe time course of bone fractures observed in the ATAC (‘Arimidex’, Tamoxifen, Alone or in Combination) trialProc Am Soc Clin Oncol20032225 abs 98
   Google Scholar
• McCloskeyEEastellRLaknerGInitial results from the LEAP study:the first direct comparison of safety parameters between aromatase inhibitors in healthy postmenipausal womenSan Antonio Breast Cancer Symposium2005 abstr 2052
   Google Scholar
• MillerWRDixonJMEndocrine and clinical endpoints of exemestane as neoadjuvant therapyCancer Control200292 Suppl91511965226
   PubMedGoogle Scholar
• MouridsenHGershanovichMSunYPhase III study of letrozole versus tamoxifen as first-line therapy of advanced breast cancer in postmenopausal women:analysis of survival and update of efficacy from the International Letrozole Breast Cancer GroupJ Clin Oncol2003212101912775735
   PubMed Web of Science ®Google Scholar
• NabholtzJMBuzdarAPollakMAnastrozole is superior to tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women:results of a North American multicenter randomized trial. Arimidex Study GroupJ Clin Oncol20001837586711078488
   PubMed Web of Science ®Google Scholar
• NabholtzJMBonneterreJBuzdarAAnastrozole (Arimidex) versus tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women:survival analysis and updated safety resultsEur J Cancer2003391684912888362
   PubMed Web of Science ®Google Scholar
• NabholtzJMGlogorovJCardiovascular safety profiles of aromatase inhibitors:a comparative reviewDrug Saf20062978580116944964
   PubMed Web of Science ®Google Scholar
• ParkinDMBrayFFerlayJGlobal cancer statistics, 2002CA Cancer J Clin2005557410815761078
   PubMed Web of Science ®Google Scholar
• ParidaensRTherassePDirixLFirst line hormonal treatment (HT) for metastatic breast cancer (MBC) with exemestane (E) or tamoxifen (T) in postmenopausal patients (pts) – A randomized phase III trial of the EORTC Breast GroupProc ASCO200423 abs 515
   Google Scholar
• PerezNBorjaJAromatase inhibitors:clinical pharmacology and therapeutic implications in breast cancerJ Int Med Res199220303121387368
   PubMed Web of Science ®Google Scholar
• PowlesTJHickishTKanisJEffect of tamoxifen on bone mineral density measured by dual-energy x-ray absorptiometry in healthy premenopausal and postmenopausal womenJ Clin Oncol19961478848558225
   PubMed Web of Science ®Google Scholar
• RingADowsettMMechanisms of tamoxifen resistanceEndocr Relat Cancer2004116435815613444
   PubMed Web of Science ®Google Scholar
• RoseCVtorayaOPluzanskaAAn open randomised trial of second-line endocrine therapy in advanced breast cancer. comparison of the aromatase inhibitors letrozole and anastrozoleEur J Cancer20033923182714556923
   PubMed Web of Science ®Google Scholar
• RossouwJEAndersonGLPrenticeRLRisks and benefits of estrogen plus progestin in healthy postmenopausal women:Principal results from the Women’s Health Initiative randomized controlled trialJAMA20022883213312117397
   PubMed Web of Science ®Google Scholar
• SamojlikEVeldhuisJDWellsSAPreservation of androgen secretion during estrogen suppression with aminoglutethimide in the treatment of metastatic breast carcinomaJ Clin Invest198065602126986409
   PubMed Web of Science ®Google Scholar
• SaphnerTTormeyDCGrayRAnnual hazard rates of recurrence for breast cancer after primary therapyJ Clin Oncol1996142738468874335
   PubMed Web of Science ®Google Scholar
• SchmidMJakeszRSamoniggHRandomized trial of tamoxifen versus tamoxifen plus aminoglutethimide as adjuvant treatment in postmenopausal breast cancer patients with hormone receptor-positive disease:Austrian breast and colorectal cancer study group trial 6J Clin Oncol2003219849012637461
   PubMed Web of Science ®Google Scholar
• SchmittMKuhnWHarbeckNThrombophilic state in breast cancerSemin Thromb Hemost1999251576610357083
   PubMed Web of Science ®Google Scholar
• SegaloffAWeethJBMeyerKKHormonal therapy in cancer of the breast. 19. Effect of oral administration of delta-1-testolactoneon clinical course and hormonal excretionCancer1962156335
   Web of Science ®Google Scholar
• WasanKMGossPPritchardPThe influence of letrozole on serum lipid concentrations in postmenopausal women with primary breast cancer who have completed 5 years of adjuvant tamoxifen (NCIC CTG MA.17L)Ann Oncol2005167071515817595
   PubMed Web of Science ®Google Scholar
• WhelanTJGossPEIngleJNAssessment of quality of life in MA 17:a randomized, placebo-controlled trial of letrozole after 5 years of tamoxifen in postmenopausal womenJ Clin Oncol20052369314016157934
   PubMed Web of Science ®Google Scholar
• WinerEPHudisCBursteinHJAmerican Society of Clinical Oncology Technology Assessment on the use of aromatase inhibitors as adjuvant therapy for postmenopausal women with hormone receptor-positive breast cancer:status report 2004J Clin Oncol2005236192915545664
   PubMed Web of Science ®Google Scholar
• WisemanLRMcTavishDFormestane. A review of its pharmaco-dynamic and pharmacokinetic properties and therapeutic potential in the management of breast cancer and prostatic cancerDrugs19934566847680986
   PubMed Web of Science ®Google Scholar
• WojtackiJLesniewski-KmakKPawlakWAnastrozole therapy and lipid profile:an updateEur J Cancer20042142
   Web of Science ®Google Scholar
• WojtackiJLesniewski-KmakKBiochemical markers of the risk for cardiovascular disease in women with early breast cancer treated with anastrozoleEur J Cancer20053105
   Google Scholar
• WysowskiDKHonigSBeitzJUterine sarcoma associated with tamoxifen useN Engl J Med20023461832312050351
   PubMed Web of Science ®Google Scholar